Company / Financials
RHYTHM PHARMACEUTICALS, INC. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$189.8M
FY2025 · +45.8% YoY
Net Income
-$196.5M
FY2025 · +24.6% YoY
Profit Margin
-103.6%
FY2025 · net income / revenue
ROE
-141.3%
FY2025 · return on equity
Total Assets
$480.2M
FY2025
Total Debt
$100.9M
0.73x debt/equity
Equity
$139.1M
FY2025
ROA
-40.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$189.8M+45.8% YoYNet Income HistoryProfit after all expenses and taxes-$196.5M+24.6% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$19.5M+45.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$192.0M+27.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$194.9M+35.1% YoYR&D Expense HistoryResearch and development spending$167.3M-29.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$13.9MIncome Tax HistoryTotal income tax expense$497.0K+43.6% YoYEPS (Basic) HistoryBasic earnings per share-$3.20+7.8% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.200.0% YoY